// App-Quantinova.ai

8031 : Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.

Researchers

Presenter

  • Philippe Moreau

Principal Investigators

  • Meletios A. Dimopoulos

  • Paul G. Richardson

  • David Samuel DiCapua Siegel

  • Antonio Palumbo

  • Michele Cavo

  • Paolo Corradini

  • Katja Weisel

  • Michel Delforge

  • Peter O'Gorman

  • Kevin W. Song

  • Lars Axel Sternas

  • Teresa Peluso

  • Kevin Hong

  • Jennifer Herring

  • Xin Yu

  • Mohamed H. Zaki

  • Jesus San Miguel

Medical Centers

  • CHU de Nantes - Hotel Dieu, Nantes, France

  • School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

  • Dana-Farber Cancer Institute, Boston, MA

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Department of Hematology, University of Torino, Torino, Italy

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • University of Tubingen, Tubingen, Germany

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • School of Medicine and Medical Science, University College Dublin, Dublin, Ireland

  • Vancouver General Hospital, Vancouver, BC, Canada

  • Celgene Corporation, Summit, NJ

  • Celgene International Sarl, Boudry, Switzerland

  • Clinica Universidad de Navarra, Pamplona, Spain

Locations

  • Ireland

  • Canada

  • Italy

  • Greece

  • Germany

  • Spain

  • Switzerland

  • United States

  • France

  • Belgium

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00833833

  • NCT01311687

  • NCT01712789

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved